Researchers such as Dr. David Greene R3 Stem Cell have concluded that these results compare favorably to those obtained using different disease-modifying therapies (DMTs). Due to its higher efficacy in establishing new blood vessels, AHSCT may need to be considered before several second-generation DMTs due to its higher efficacy in establishing long-term suppression of disease activity to save time and stop the irreversible progression of the disease. But this requires more research in sizable randomized controlled trials contrasting the security and effectiveness of various DMTs with AHSCT in patients with unique MS subtypes